

## HPMS E-Mail

**Date:** December 29, 2021

**Subject:** Part D Drug Management Program – Revised Standardized Beneficiary Notices and Instructions

CMS announces the availability of updated standardized beneficiary notices and instructions for Part D Drug Management Programs (DMPs), currently pending approval by the Office of Management and Budget (OMB). We are providing the revised notices in advance of OMB approval to give plan sponsors as much time as possible to update their systems with the updated language incorporating various program changes for DMPs.

Part D sponsors are required to communicate in writing with beneficiaries for whom they intend to limit access to coverage for frequently abused drugs (FADs) (42 CFR § 423.153(f)(4)(c)). Sponsors must use the standardized notices and may not develop their own (42 CFR § 423.153(f)(5)(ii)(A) and (6)(ii)(A)). Until the updated notices are approved by OMB, which will be announced through HPMS, sponsors should continue to use the existing, approved beneficiary notices.

The revised notices and instructions ([CY 2022 Drug Management Program Notices](#)), currently approved notices and instructions ([CY 2021 Drug Management Program Notices](#)), as well as DMP policy and technical guidance are posted in “Downloads” on the CMS Part D Overutilization web page at: <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/RxUtilization>.

Questions about DMPs and these beneficiary notices may be submitted to [PartD\\_OM@cms.hhs.gov](mailto:PartD_OM@cms.hhs.gov).